F
FRE
vs
S
S&P/ASX 300
Over the past 12 months, FRE has underperformed S&P/ASX 300, delivering a return of -17% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
FRE vs S&P/ASX 300
Performance Gap
FRE vs S&P/ASX 300
Performance By Year
FRE vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is focused to develop Nasodine, a nasal spray that contains the broad spectrum antimicrobial agent called povidone-iodine. The firm is engaged in product formulation, packaging and manufacturing development. Nasodine nasal spray medicine targets the cause of colds, where they start in the nose. Its nasal spray is responsible for respiratory infections, such as the common cold. The firm's Series C funding, Phase III trial has been completed.
